Preface vii

I. Transport Mechanisms Across Membranes 1

Biophysical model approaches to mechanistic transepithelial studies of peptides
N.F.H. Ho, J.S. Day, C.L. Barsuhn, P.S. Burton and T.J. Raub (Kalamazoo, MI, U.S.A.) 3
Transport and permeability properties of human Caco-2 cells: an *in vitro* model of the intestinal epithelial cell barrier
G. Wilson, I.F. Hassan, C.J. Dix, I. Williamson, R. Shah, M. Mackay (Horsham, Great Britain) and P. Artursson (Uppsala, Sweden) 25
Nutrient effects on intestinal drug absorption
D. Fleisher, C.L. Lippert, N. Sheth, C. Reppas and J. Wlodyga (Ann Arbor, MI, U.S.A.) 41
Blood–brain barrier: mechanisms of peptide regulation and transport
K.L. Audus (Lawrence, KS, U.S.A.) 51
Delivery of vital drugs to the brain for the treatment of brain tumors
N.H. Greig, S. Genka and S.I. Rapoport (Bethesda, MD, U.S.A.) 61
Mechanisms and facilitation of corneal drug penetration
V.H.L. Lee (Los Angeles, CA, U.S.A.) 79

II. Transdermal and Iontophoretic Delivery 91

Solvent-mediated alterations of the stratum corneum
K. Knutson, S.L. Krill and J. Zhang (Salt Lake City, UT, U.S.A.) 93
Electrochemical and iontophoretic studies of human skin
J.D. DeNuzzio and B. Berner (Ardsley, NY, U.S.A.) 105
A comparison of pulsed and continuous current iontophoresis
T. Bagniefski and R.R. Burnette (Madison, WI, U.S.A.) 113
In vitro and *in vivo* evaluation of transdermal iontophoretic delivery of hydromorphone
R.V. Padmanabhan, J.B. Phipps, G.A. Lattin and R.J. Sawchuk (Minneapolis, MN, U.S.A.) 123

III. Proteins and Macromolecular Drug Delivery 137

The clinical efficacy of poly(ethylene glycol)-modified proteins
F. Fuertges and A. Abuchowski (Plainfield, NJ, U.S.A.) 139
Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules: uricase–dextran conjugate
T. Fujita, Y. Yasuda, Y. Takakura, M. Hashida and H. Sezaki (Kyoto, Japan) 149
Cell delivery and tissue regeneration
A.I. Caplan (Cleveland, OH, U.S.A.) 157
Albumin–heparin microspheres as carriers for cytostatic agents
H.F.M. Cremers, J. Feijen (Enschede, The Netherlands), G. Kwon, Y.H. Bae, S.W. Kim (Salt Lake City, UT, U.S.A.), H.P.J.M. Noteborn and J.G. McVie (Amsterdam, The Netherlands) 167
Mechanochemical approaches to self-regulating insulin pump design
R.A. Siegel and B.A. Firestone (San Francisco, CA, U.S.A.) 181
Self-regulated glycosylated insulin delivery
S.W. Kim, C.M. Pai, K. Makino, L.A. Seminoff, D.L. Holmberg, J.M. Gleeson, D.E. Wilson and E.J. Mack (Salt Lake City, UT, U.S.A.) 193

IV. Microspheres, Liposomes and Other Delivery Systems 203

Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches
J.H. Eldridge, C.J. Hammond, J.A. Meulbroek, J.K. Staas, R.M. Gilley and T.R. Tice (Birmingham, AL, U.S.A.) 205
Preparation and permeability characteristics of microcapsule membranes
T. Kondo (Tokyo, Japan) 215
Liposomes as a delivery system for membrane-active antitumor drugs
R.L. Juliano and S.S. Daoud (Chapel Hill, NC, U.S.A.) 225

Drug-laden liposomes in antitumor therapy and in the treatment of parasitic diseases
D.J.A. Crommelin, U.K. Nässander, P.A.M. Peeters (Utrecht, The Netherlands), P.A. Steerenberg, W.H. de Jong (Bilthoven, The Netherlands), W.M.C. Eling (Nijmegen, The Netherlands) and G. Storm (Menlo Park, CA, U.S.A.).....233
Controlled release implants for cardiovascular disease
R.J. Levy (Ann Arbor, MI, U.S.A.), T.P. Johnston (Chicago, IL, U.S.A.), A. Sintov and G. Golomb (Jerusalem, Israel).....245
Thermally on–off switching polymers for drug permeation and release
T. Okano, Y.H. Bae, H. Jacobs and S.W. Kim (Salt Lake City, UT, U.S.A.).....255

V. Targeting and Site-specific Delivery.....267

Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylene glycol)–poly(aspartic acid) block copolymer
M. Yokoyama, M. Miyauchi, N. Yamada, T. Okano, Y. Sakurai (Tokyo, Japan), K. Kataoka (Chiba, Japan) and S. Inoue (Tokyo, Japan).....269
The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery
J. Kopeček (Salt Lake City, UT, U.S.A.).....279
Peptide sequences that target proteins for lysosomal degradation
J.F. Dice (Boston, MA, U.S.A.).....291
Antibody-linked chelating polymers for immunoimaging *in vivo*
V.P. Torchilin, A.L. Klibanov, M.A. Slinkin, S.M. Danilov, D.O. Levitsky (Moscow, U.S.S.R.) and B.A. Khaw (Boston, MA, U.S.A.).....297

VI. Pharmacokinetics and Pharmacodynamics.....305

A structured approach to the development of a controlled-release drug delivery system for a β-adrenoceptor blocking drug
V.A. John (Ardsley, NY, U.S.A.).....307
Clinical pharmacology and controlled drug delivery: the renin–angiotensin system
W.R. Good and A.J. Piraino (Summit, NJ, U.S.A.).....315
Clinical pharmacology approaches to the assessment of novel drug delivery concepts
S.R. Pollock and L.S. Olanoff (Kalamazoo, MI, U.S.A.).....331
Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery
N.A. Mazer (Salt Lake City, UT, U.S.A.).....343
Author Index.....357
Subject Index.....358